AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

The K-Map Study, Global Prevalence of KC

Recruitingn/aAges 6 Years - 23 YearsAllUniversity Hospital, Geneva
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Keratoconus is a ocular disease classified under ectatic diseases which often results in bilateral and asymmetrical corneal distortion. It usually affects patients at young age and can cause severe visual loss. The overall goal of this study is to assess the prevalence of keratoconus (KC) in children and adolescents in various regions of the world based on modern tomographic imaging methods, and to verify whether the occurrence rates reported from literature should be corrected. Our hypothesis is that the prevalence of the disease is much higher than that traditionally reported. At each site, corneal tomography examinations (Pentacam) will be performed bilaterally in children and adolescents, who are not ill or with any ophthalmological symptom. The population to be studied will be composed of children and adolescents on medical visits for non-ophthalmologic reasons, aged between 6 and

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Male or female, 6-23 years of age. * Subjects seen for a non-ophthalmic appointment * Provide signed and dated patient consent form (signed by parents / legal guardians). * Willing to comply with all study procedures and be available for the duration of the study Exclusion Criteria: * Patients with a preexisting ocular disease / condition * Pregnancy or breastfeeding
๐Ÿ’Š

What it tests

  • Rotating Scheimpflug camera (Pentacam HR)
๐Ÿ“

Where

12 sites
USC Roski Eye Institute
Los Angeles, United States
Eye Hospital of Wenzhou Medical College
Wenzhou, China
โ€”
Zagreb, Croatia
โ€”
Alexandria, Egypt
โ€”
Homburg, Germany
โ€”
Isfahan, Iran
โ€”
Amman, Jordan
โ€”
Monterrey, Mexico

โ€ฆand 4 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy